Xeris Biopharma Q1 total revenue $40.6M (+22% YoY); tightens FY 2024 guidance to $175M-$200M

Xeris Biopharma Holdings, Inc.

2024-FY EPS reported -$0.14 revenue$40,638,000

Net product revenue $40.3M (+24.8% YoY); Recorlev revenue $10.6M (+136.7%).
Net loss $19.0M ($0.14/share); cash $87.4M at March 31, 2024 (up from $72.5M).
Entered exclusive license with Amgen for XeriJect teprotumumab; up to $75M milestones plus royalties.
Entered collaboration with Beta Bionics for XeriSol glucagon in bi-hormonal pumps.
Tightened FY 2024 total revenue guidance to $175M-$200M; lowered Hayfin debt rate by 2.05%.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Xeris Biopharma Holdings, Inc. reported first quarter ended March 31, 2024 results: revenue $40,638, net income $19.0 million, or $0.14 per share. Guidance reaffirmed.

Period: first quarter ended March 31, 2024
Revenue: $40,638
Net income: $19.0 million, or $0.14 per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

13,085 12,755 330 2.6 Recorlev 10,599 4,477 6,122 136.7 Product revenue, net 40,263 32,265 7,998 24.8 Royalty, contract and other revenue 375 931 (556) (59.7) Total revenue $ 40,638 $ 33,196 $ 7,442 22.4 Commercial Products • Gvoke® : First quarter net revenue was $16.6 million as compared to $15.0 million in the first quarter of 2023 – an increase of

View on SEC.gov

1050 earnings releases filed in the last 30 days. Browse all earnings releases →

Xeris Biopharma Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001867096-24-000062

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.